1. Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial. (December 2020) Authors: Ray, K.K.; Kallend, D.; Leiter, L.A.; Raal, F.J.; Koenig, W.; Jaros, M.J.; Schwartz, G.G.; Landmesser, U.; Wijngaard, P.L.; Wright, R.S.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of inclisiran on haematological and immunological biomarkers: A Pooled analysis of ORION-9, -10 and -11 trial data. (August 2021) Authors: Landmesser, U.; Conde, L. Garcia; Wright, R.S.; Raal, F.J.; Koenig, W.; Leiter, L.A.; Schwartz, G.G.; Kallend, D.G.; Lawrence, D.; Ray, K.K. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy, Safety And Pharmacokinetics Of Inclisiran By Renal Function. (August 2019) Authors: Kallend, D.; Collins, M.; Kastelein, J.; Landmesser, U.; Leiter, L.; Ray, K.; Robson, R.; Stoekenbroek, R.; Wright, R.S.; Wijngaard, P. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia. (December 2020) Authors: Raal, F.J.; Kallend, D.; Ray, K.K.; Turner, T.A.; Koenig, W.; Wright, R.S.; Wijngaard, P.L.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; Landmesser, U.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗